Efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in Chinese women aged 18–25 years: event‐triggered analysis of a randomized …
F Zhu, SY Hu, Y Hong, YM Hu, X Zhang… - Cancer …, 2017 - Wiley Online Library
We previously reported the results of a phase II/III, double‐blind, randomized controlled
study in Chinese women (NCT00779766) showing a 94.2%(95% confidence interval: 62.7 …
study in Chinese women (NCT00779766) showing a 94.2%(95% confidence interval: 62.7 …
Efficacy, immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese women aged 18–25 years: results from a randomized controlled …
FC Zhu, W Chen, YM Hu, Y Hong, J Li… - … Journal of Cancer, 2014 - Wiley Online Library
This phase II/III, double‐blind, randomized trial assessed the efficacy, immunogenicity and
safety of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in young …
safety of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in young …
Efficacy, immunogenicity and safety of the AS04‐HPV‐16/18 vaccine in Chinese women aged 18‐25 years: End‐of‐study results from a phase II/III, randomised …
FC Zhu, SY Hu, Y Hong, YM Hu, X Zhang… - Cancer …, 2019 - Wiley Online Library
Background Cervical cancer is a major public health concern in China. We report the end‐of‐
study results of a phase II/III trial to assess the efficacy, immunogenicity, and safety of the …
study results of a phase II/III trial to assess the efficacy, immunogenicity, and safety of the …
Efficacy of human papillomavirus type 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double-blind, randomized …
R Konno, S Tamura, K Dobbelaere… - International Journal of …, 2010 - ijgc.bmj.com
Background: Human papillomavirus (HPV) type 16/18 AS04-adjuvanted vaccine was shown
to be highly immunogenic and generally well tolerated in the interim analysis of a phase 2 …
to be highly immunogenic and generally well tolerated in the interim analysis of a phase 2 …
Efficacy of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double-blind, randomized …
R Konno, S Tamura, K Dobbelaere… - International Journal of …, 2010 - ijgc.bmj.com
Background: A phase 2 double-blind, controlled, randomized multicenter study with human
papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine is ongoing in healthy Japanese …
papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine is ongoing in healthy Japanese …
Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15–25 years with and without serological evidence of previous exposure …
A Szarewski, WAJ Poppe, SR Skinner… - … journal of cancer, 2012 - Wiley Online Library
Abstract In the Phase III PATRICIA study (NCT00122681), the human papillomavirus (HPV)‐
16/18 AS04‐adjuvanted vaccine (Cervarix®, GlaxoSmithKline Biologicals) was highly …
16/18 AS04‐adjuvanted vaccine (Cervarix®, GlaxoSmithKline Biologicals) was highly …
Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women
N De Carvalho, J Teixeira, CM Roteli-Martins, P Naud… - Vaccine, 2010 - Elsevier
We report efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3
years post-vaccination. The study was conducted in a population (N= 433) of women …
years post-vaccination. The study was conducted in a population (N= 433) of women …
Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese …
R Konno, H Yoshikawa, M Okutani… - Human Vaccines & …, 2014 - Taylor & Francis
In this open, extended follow-up study (NCT00929526, Clinicaltrials. gov), we evaluated the
human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine efficacy, immunogenicity and …
human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine efficacy, immunogenicity and …
Efficacy of the AS04-adjuvanted HPV16/18 vaccine: pooled analysis of the Costa Rica Vaccine and PATRICIA randomized controlled trials
Abstract Background The AS04-adjuvanted HPV16/18 (AS04-HPV16/18) vaccine provides
excellent protection against targeted human papillomavirus (HPV) types and a variable …
excellent protection against targeted human papillomavirus (HPV) types and a variable …
Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women …
MH Einstein, P Takacs, A Chatterjee… - Human vaccines & …, 2014 - Taylor & Francis
The observer-blind, randomized, age-stratified, head-to-head study (NCT00423046)
comparing immunogenicity and safety of HPV-16/18 and HPV-6/11/16/18 vaccines in …
comparing immunogenicity and safety of HPV-16/18 and HPV-6/11/16/18 vaccines in …